BR0211535A - Derivados de imidazolidina, sua preparação e seu uso como antagonistas de vla-4 - Google Patents
Derivados de imidazolidina, sua preparação e seu uso como antagonistas de vla-4Info
- Publication number
- BR0211535A BR0211535A BR0211535-2A BR0211535A BR0211535A BR 0211535 A BR0211535 A BR 0211535A BR 0211535 A BR0211535 A BR 0211535A BR 0211535 A BR0211535 A BR 0211535A
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- compounds
- vla
- antagonists
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"DERIVADOS DE IMIDAZOLIDINA, SUA PREPARAçãO E SEU USO COMO ANTAGONISTAS DE VLA-4". A presente invenção refere-se a novos derivados imidazolidina da fórmula (I), onde B, E, W, Y, R, R^ 2^, R^ 3^, R^ 30^, e e h têm os significados dados nas reivindicações. Os compostos da fórmula (I) são valiosos compostos farmacêuticos ativos que são apropriados, por exemplo, para tratamento de doença inflamatória, por exemplo artrite reumatóide, ou doenças alérgicas. Os compostos da fórmula (I) são inibidores da adesão e migração de leucócitos e/ou antagonistas do receptor de adesão VLA-4, que pertencem ao grupo de integrinas. Eles são genericamente apropriados para tratamento de doenças que são causadas por, ou associadas com, um indesejável grau de adesão de leucócito e/ou migração de leucócitos ou onde interações célula célula ou célula - matriz, que são baseadas nas interações de receptores VLA-4 com seus ligantes, desempenham um papel. A invenção além disso refere-se a processos para preparação de compostos da fórmula (I), a seu uso e preparações farmacêuticas que compreendem compostos da fórmula (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10137595A DE10137595A1 (de) | 2001-08-01 | 2001-08-01 | Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung |
PCT/EP2002/008106 WO2003011288A1 (en) | 2001-08-01 | 2002-07-20 | Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0211535A true BR0211535A (pt) | 2004-07-13 |
Family
ID=7693930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0211535-2A BR0211535A (pt) | 2001-08-01 | 2002-07-20 | Derivados de imidazolidina, sua preparação e seu uso como antagonistas de vla-4 |
Country Status (30)
Country | Link |
---|---|
US (1) | US6962937B2 (pt) |
EP (1) | EP1414444B1 (pt) |
JP (1) | JP4676697B2 (pt) |
KR (1) | KR100910930B1 (pt) |
CN (1) | CN1537000B (pt) |
AR (1) | AR036349A1 (pt) |
AT (1) | ATE391504T1 (pt) |
AU (1) | AU2002328931B2 (pt) |
BR (1) | BR0211535A (pt) |
CA (1) | CA2455966C (pt) |
CO (1) | CO5550452A2 (pt) |
DE (2) | DE10137595A1 (pt) |
DK (1) | DK1414444T3 (pt) |
ES (1) | ES2301673T3 (pt) |
HK (1) | HK1066166A1 (pt) |
HR (1) | HRP20040108A2 (pt) |
HU (1) | HUP0401406A3 (pt) |
IL (2) | IL160093A0 (pt) |
MX (1) | MXPA04000041A (pt) |
MY (1) | MY133467A (pt) |
NO (1) | NO326696B1 (pt) |
NZ (1) | NZ530887A (pt) |
PE (1) | PE20030348A1 (pt) |
PL (1) | PL365396A1 (pt) |
PT (1) | PT1414444E (pt) |
RS (1) | RS6104A (pt) |
RU (1) | RU2318815C2 (pt) |
TW (1) | TWI325863B (pt) |
WO (1) | WO2003011288A1 (pt) |
ZA (1) | ZA200400194B (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4617449B2 (ja) | 2002-07-11 | 2011-01-26 | ヴィキュロン ファーマシューティカルズ インコーポレイテッド | 抗菌活性を有するn−ヒドロキシアミド誘導体 |
EP2093218A1 (en) * | 2008-02-22 | 2009-08-26 | Ruggero Fariello | Arylalkyl substituted imidazolidinones |
JP2011519926A (ja) * | 2008-05-05 | 2011-07-14 | ウィンスロップ−ユニバーシティー ホスピタル | Cox阻害薬の心血管系リスク因子の改善方法 |
EP3326645B1 (en) | 2010-10-25 | 2020-03-18 | Biogen MA Inc. | Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE235866C (pt) | ||||
DE4009506A1 (de) * | 1990-03-24 | 1991-09-26 | Hoechst Ag | Hydantoinderivate |
DE4126277A1 (de) * | 1991-08-08 | 1993-02-11 | Cassella Ag | Hydantoinderivate |
EP0626861B2 (en) | 1992-01-13 | 2004-04-28 | Biogen, Inc. | Treatment for asthma |
DK0625912T3 (da) | 1992-02-12 | 1997-10-27 | Biogen Inc | Behandling af inflammatorisk tarmsygdom |
DE4207254A1 (de) | 1992-03-07 | 1993-09-09 | Cassella Ag | 4-oxo-2-thioxoimidazolidin-derivate |
DE4213634A1 (de) * | 1992-04-24 | 1993-10-28 | Cassella Ag | 2,4-Dioxo-imidazolidin-Derivate |
DE4224414A1 (de) * | 1992-07-24 | 1994-01-27 | Cassella Ag | Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung |
DE4228717A1 (de) * | 1992-08-28 | 1994-03-03 | Cassella Ag | Imidazolidin-Derivate |
WO1994015958A2 (en) | 1993-01-08 | 1994-07-21 | Tanabe Seiyaku Co., Ltd. | Peptide inhibitors of cell adhesion |
NZ261259A (en) | 1993-01-12 | 1996-12-20 | Biogen Inc | Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments |
AU687790B2 (en) | 1993-02-09 | 1998-03-05 | Biogen Idec Ma Inc. | Treatment for insulin dependent diabetes |
DE4308034A1 (de) * | 1993-03-13 | 1994-09-15 | Cassella Ag | Neue Heterocyclen, ihre Herstellung und ihre Verwendung |
DE4427979A1 (de) * | 1993-11-15 | 1996-02-15 | Cassella Ag | Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung |
AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
EP0804237B8 (en) | 1994-01-25 | 2006-11-08 | Elan Pharmaceuticals, Inc. | Humanized antibodies against leukocyte adhesion molecule vla-4 |
CA2193828A1 (en) | 1994-06-29 | 1996-01-11 | Timothy P. Kogan | Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin |
US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
DE19515177A1 (de) | 1995-04-28 | 1996-10-31 | Cassella Ag | Hydantoinderivate als Zwischenprodukte für pharmazeutische Wirkstoffe |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
EP0796855B1 (de) * | 1996-03-20 | 2002-02-06 | Hoechst Aktiengesellschaft | Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
AU3738597A (en) | 1996-07-25 | 1998-02-20 | Biogen, Inc. | Molecular model for vla-4 inhibitors |
DE19647380A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
DE19647381A1 (de) * | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
PL323130A1 (en) * | 1996-11-15 | 1998-05-25 | Hoechst Ag | Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such |
WO1998042656A1 (en) | 1997-03-21 | 1998-10-01 | Cytel Corporation | Novel compounds |
DE19741235A1 (de) | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE19741873A1 (de) * | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
JP4555468B2 (ja) | 1997-10-31 | 2010-09-29 | アベンテイス・フアルマ・リミテツド | 置換アニリド |
GB9723789D0 (en) | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
DE19751251A1 (de) * | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
WO1999054321A1 (en) | 1998-04-21 | 1999-10-28 | Aventis Pharma Limited | Substituted diamines and their use as cell adhesion inhibitors |
DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
TR200003848T2 (tr) | 1998-06-30 | 2001-06-21 | Pfizer Products Inc. | VLA-4'e bağlı hücre bağlanmasının peptidil olmayan önleyicileri. |
AU1915399A (en) | 1998-07-10 | 2000-02-01 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
DE19922462A1 (de) * | 1999-05-17 | 2000-11-23 | Aventis Pharma Gmbh | Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate |
-
2001
- 2001-08-01 DE DE10137595A patent/DE10137595A1/de not_active Withdrawn
-
2002
- 2002-07-20 BR BR0211535-2A patent/BR0211535A/pt active Search and Examination
- 2002-07-20 RS YU6104A patent/RS6104A/sr unknown
- 2002-07-20 CA CA2455966A patent/CA2455966C/en not_active Expired - Fee Related
- 2002-07-20 DE DE60226032T patent/DE60226032T2/de not_active Expired - Lifetime
- 2002-07-20 PT PT02764740T patent/PT1414444E/pt unknown
- 2002-07-20 PL PL02365396A patent/PL365396A1/xx not_active Application Discontinuation
- 2002-07-20 KR KR1020047001524A patent/KR100910930B1/ko not_active IP Right Cessation
- 2002-07-20 AT AT02764740T patent/ATE391504T1/de active
- 2002-07-20 JP JP2003516518A patent/JP4676697B2/ja not_active Expired - Fee Related
- 2002-07-20 ES ES02764740T patent/ES2301673T3/es not_active Expired - Lifetime
- 2002-07-20 RU RU2004105966/04A patent/RU2318815C2/ru not_active IP Right Cessation
- 2002-07-20 NZ NZ530887A patent/NZ530887A/en not_active IP Right Cessation
- 2002-07-20 HU HU0401406A patent/HUP0401406A3/hu unknown
- 2002-07-20 WO PCT/EP2002/008106 patent/WO2003011288A1/en active IP Right Grant
- 2002-07-20 CN CN028151046A patent/CN1537000B/zh not_active Expired - Fee Related
- 2002-07-20 EP EP02764740A patent/EP1414444B1/en not_active Expired - Lifetime
- 2002-07-20 DK DK02764740T patent/DK1414444T3/da active
- 2002-07-20 MX MXPA04000041A patent/MXPA04000041A/es active IP Right Grant
- 2002-07-20 IL IL16009302A patent/IL160093A0/xx unknown
- 2002-07-20 AU AU2002328931A patent/AU2002328931B2/en not_active Ceased
- 2002-07-26 PE PE2002000672A patent/PE20030348A1/es not_active Application Discontinuation
- 2002-07-30 MY MYPI20022873A patent/MY133467A/en unknown
- 2002-07-30 TW TW091116941A patent/TWI325863B/zh not_active IP Right Cessation
- 2002-07-30 AR ARP020102868A patent/AR036349A1/es active IP Right Grant
- 2002-07-31 US US10/208,182 patent/US6962937B2/en not_active Expired - Lifetime
-
2004
- 2004-01-12 ZA ZA200400194A patent/ZA200400194B/xx unknown
- 2004-01-26 CO CO04005444A patent/CO5550452A2/es not_active Application Discontinuation
- 2004-01-27 IL IL160093A patent/IL160093A/en not_active IP Right Cessation
- 2004-01-30 HR HR20040108A patent/HRP20040108A2/hr not_active Application Discontinuation
- 2004-01-30 NO NO20040426A patent/NO326696B1/no not_active IP Right Cessation
- 2004-11-18 HK HK04109104.0A patent/HK1066166A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9804695A (pt) | Derivados de imidazolidina substituìdos, sua preparação, sua aplicação de preparações farmacêuticas contendo os mesmos | |
BR9705727A (pt) | Heterocicilos com anel de cinco membros como inibidores da adesão de leucócitos e como antigonistas de vla-4. | |
DE59915127D1 (de) | Imidazolidinderivate, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate | |
BR9705725A (pt) | Heterociclos como inibidores da adesão de leucócitos e antagonistas de vla-4 | |
BR0210344A (pt) | Inibidores da hiv protease, composições contendo os mesmos, seus usos farmacêuticos e materiais para a sua sìntese | |
BR0316234A (pt) | Hidroxiindóis, seu uso como inibidores de fosfodiesterase 4 e processos para a preparação dos mesmos | |
AR007353A1 (es) | Empleo de inhibidores del intercambio de na(+)/h(+) (nhe) celular para la preparacion de un medicamento para la normalizacion de los serolipidos | |
ATE150000T1 (de) | Einfluss von n,n,n-trimethylsphingosin auf die aktivität der protein-c-kinase, melanomzellwachstum in vitro, metastatisches potential in vivo und humane blutblättchenaggregation | |
ME00275B (me) | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE | |
BR0317283A (pt) | Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso | |
BRPI0414514A (pt) | uso de um composto, composto, e, composições farmacêuticas | |
BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
MEP36908A (en) | omega-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | |
BRPI0511778A (pt) | derivados da naftalina úteis como ligantes do receptor 3 da histamina | |
BR0111264A (pt) | Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização | |
BR9803969A (pt) | Novos heterociclos de anel com cinco elementos, sua preparações seu uso e preparação farmacêuticas compreendendo os mesmos | |
JP2012500809A (ja) | 免疫調節活性 | |
BR0012610A (pt) | Novo derivado de difenilpiperidina | |
NO178261C (no) | Substituerte diaminoftalimider og analoger, farmasöytiske preparater inneholdende dem samt deres anvendelse i medikamenter | |
BR0115938A (pt) | Derivados de guanidina e amidina com inibidores do fator xa | |
BR0211535A (pt) | Derivados de imidazolidina, sua preparação e seu uso como antagonistas de vla-4 | |
BR0207981A (pt) | Derivados de imidazolidina, sua preparação, e seu uso como agente antiinflamatório | |
BRPI0416745A (pt) | novos compostos | |
PT1183247E (pt) | Sistemas tiazole policiclicos e sua utilizacao como anorecticos | |
BR0011296A (pt) | Derivados de espiroimidazolidina, preparação dos mesmos, utilização dos mesmos e preparações farmacêuticas compreendendo os mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA.INT.CI.A61K 31/4166, C07D 233/72, C07D 233/74, C07D 405/12, A61K 31/4178, A61P 29/00, A61P 9/10, A61P 11/06 Ipc: A61K 31/4166 (2011.01), C07D 233/72 (2011.01), C07 |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 14A ANUIDADE. |
|
B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |